Pentlow K S, Graham M C, Lambrecht R M, Cheung N K, Larson S M
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Med Phys. 1991 May-Jun;18(3):357-66. doi: 10.1118/1.596728.
Positron emission tomography (PET) is potentially useful for the quantitative imaging of radiolabeled antibodies, leading in turn to improved dosimetry in radioimmunotherapy. Iodine-124 is a positron-emitting nuclide with appropriate chemical properties and half-life (4.2 days) for such studies since the radiolabeling of antibodies with iodine is well understood and the half-life permits measurements over several days. Unfortunately, I-124 has a complex decay scheme with many high-energy gamma rays and a positron abundance of only 25%. It has therefore been largely ignored as a PET-imaging nuclide. However, measurements made with phantoms and animals under realistic conditions using a BGO-based PET scanner have shown that satisfactory imaging and quantitation can be achieved. Investigations of spatial resolution, the linearity of regional observed count rate versus activity in the presence of other activity, and the visualization and quantitation of activity in spheres with different surrounding background activities were carried out with phantoms up to 22 cm in diameter. Compared with F-18, spatial resolution was only slightly degraded (13.5 mm FWHM vs 12 mm FWHM) while linearity was the same over a 10:1 activity range (0.015 to 0.15 MBq/ml for I-124). The visualization and quantitation of spheres was also slightly degraded when using similar imaging times. Increasing the imaging time for I-124 reduced the difference. To verify that the technique would work in vivo, measurements were made of human neuroblastoma tumors in rats which had been injected with I-124 labeled 3F8 antibody. Although the number of samples was small, good agreement was achieved between image-based measurements and direct measurements of excised 4-g tumors. Thus quantitative imaging of I-124 labeled antibodies appears to be possible under realistic conditions.
正电子发射断层扫描(PET)对于放射性标记抗体的定量成像具有潜在用途,进而可改善放射免疫治疗中的剂量测定。碘-124是一种发射正电子的核素,具有适合此类研究的化学性质和半衰期(4.2天),因为用碘对抗体进行放射性标记已为人熟知,且该半衰期允许进行数天的测量。不幸的是,碘-124具有复杂的衰变模式,伴有许多高能伽马射线,且正电子丰度仅为25%。因此,它在很大程度上被忽视作为PET成像核素。然而,使用基于BGO的PET扫描仪在实际条件下对模型和动物进行的测量表明,可以实现令人满意的成像和定量分析。使用直径达22厘米的模型对空间分辨率、在存在其他活性时区域观察到的计数率与活性的线性关系以及不同周围背景活性的球体中活性的可视化和定量分析进行了研究。与氟-18相比,空间分辨率仅略有下降(半高宽为13.5毫米对12毫米),而在10:1的活性范围内线性相同(碘-124为0.015至0.15兆贝可/毫升)。使用相似的成像时间时,球体的可视化和定量分析也略有下降。增加碘-124的成像时间可减少差异。为了验证该技术在体内是否可行,对注射了碘-124标记的3F8抗体的大鼠体内的人神经母细胞瘤肿瘤进行了测量。尽管样本数量较少,但基于图像的测量与对切除的4克肿瘤的直接测量之间取得了良好的一致性。因此,在实际条件下对碘-124标记抗体进行定量成像似乎是可行的。